Malignancy Spectrum最新文献

{"title":"Multimodal management and outcome of pediatric and adolescent malignant central nervous system tumors: A single-center retrospective study","authors":"Priyadharshini Veeralakshmanan,&nbsp;Wesley M. Jose,&nbsp;Suhas Udayakumaran,&nbsp;M. R. Bindhu,&nbsp;Debnarayan Dutta,&nbsp;Kannan Rajesh,&nbsp;Sruthi Kavalagunta,&nbsp;Renjitha Bhaskaran,&nbsp;Nikhil K. Haridas,&nbsp;M. P. Rakesh,&nbsp;Keechilat Pavithran","doi":"10.1002/msp2.70019","DOIUrl":"https://doi.org/10.1002/msp2.70019","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>There is a paucity of real-world evidence in the Indian context to address the outcome of primary brain tumors (PBTs) in children. This study aimed to describe the demographic profile, clinical characteristics, and histological features of PBTs based on the 2016 World Health Organization classification, assess the efficacy of treatment methods, and identify the factors that influence the outcome.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methodology</h3>\u0000 \u0000 <p>This is a single-institution, hospital-based study. Data were collected for pediatric patients aged 0−19 years, from September 2001 to May 2023 (22 years), who were diagnosed with malignant PBTs. Patients with radiologically or histologically proven tumors were included. Those with metastatic disease to the central nervous system were excluded. The overall survival (OS) and recurrence-free survival (RFS) were estimated using the Kaplan–Meier method.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 251 patients with pediatric brain tumors were included in this analysis. The mean age was 9.10 ± 5.54 years. The male-to-female ratio was 1.20:1. In this cohort, the most common histologies were medulloblastoma and astrocytoma. The mean survival of all patients with PBTs was 141.00 ± 7.90 months with 1-, 3-, and 8-year OS rates of 79.00%, 67.00%, and 60.00%, respectively. Medulloblastoma had 1-, 3-, and 8-year OS rates of 81.00%, 72.00%, and 65.00%, respectively. The 1-year OS rates for glioblastoma and brainstem glioma were 46.00% and 45.00%, respectively. Complete tumoral resection showed longer survival than lesser degrees of resection (<i>p</i> = 0.001). Embryonal tumors (ETs) had a better RFS of 133.60 ± 12.70 months (<i>p</i> ≤ 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>ETs have a better prognosis than glial tumors. With an improved OS, the surgical resection extent has a favorable outcome. As a chemosensitive tumor, medulloblastoma benefits most from systemic treatment and responds well to a multimodal approach.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"2 3","pages":"128-139"},"PeriodicalIF":0.0,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.70019","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145197038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical efficacy of Xiaoyao San combined with Bazhen Decoction in the treatment of insomnia in postoperative breast cancer patients","authors":"Feifei Lv,&nbsp;Xin Zhang,&nbsp;Liang Wang,&nbsp;Shaodan Li,&nbsp;Fagen Li","doi":"10.1002/msp2.70016","DOIUrl":"https://doi.org/10.1002/msp2.70016","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aimed to evaluate the effects of Xiaoyao San combined with Bazhen Decoction on insomnia in patients following breast cancer surgery.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 86 patients experiencing insomnia after breast cancer surgery were randomly assigned to either the treatment group or the control group. The treatment group received Xiaoyao San combined with Bazhen Decoction, while the control group was treated with estazolam tablets. The treatment duration was 4 weeks. Pittsburgh Sleep Quality Index (PSQI) scores were assessed before and after treatment. The overall efficacy and incidence of adverse reactions were compared between the two groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>PSQI scores in both groups significantly decreased after treatment (<i>p</i> &lt; 0.05). Total effective rate in the treatment group (93.02%) was higher than that in the control group (86.05%), although the difference was not statistically significant (<i>p</i> &gt; 0.05). The incidence of adverse reactions in the treatment group (4.65%) was significantly lower than that in the control group (20.93%) (<i>p</i> &lt; 0.05).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Xiaoyao San combined with Bazhen Decoction can effectively improve sleep quality in patients with insomnia following breast cancer surgery, demonstrating good clinical efficacy and fewer adverse reactions. Further studies are needed to confirm these findings and explore broader clinical applications.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"2 3","pages":"145-150"},"PeriodicalIF":0.0,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.70016","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145196845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary mediastinal synovial sarcoma in an infant: A case report","authors":"Şule Çalışkan Kamış,&nbsp;Begül Yağcı","doi":"10.1002/msp2.70017","DOIUrl":"https://doi.org/10.1002/msp2.70017","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Primary mediastinal synovial sarcoma (PMSS) is an uncommon and aggressive soft tissue tumor, particularly rare in infants. Its diagnosis is challenging due to overlapping features with other thoracic neoplasms and requires integration of histopathology, immunohistochemistry, and molecular genetics.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case presentation</h3>\u0000 \u0000 <p>We present a case of a 4-month-old girl admitted with respiratory distress and found to have a large posterior mediastinal mass. Histopathology and immunohistochemistry were compatible with biphasic synovial sarcoma. However, molecular confirmation via detection of <i>SS18-SSX</i> fusion was not performed. Despite multimodal chemotherapy, the tumor progressed, and complete surgical resection was unachievable. The patient died during follow-up in the pediatric intensive care unit.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Accurate diagnosis is critically dependent on <i>SS18-SSX</i> molecular testing, particularly in infants. Incomplete resection and lack of genetic confirmation may contribute to poor prognosis. Literature supports that complete resection is the only consistent predictor of survival. This case illustrates the limitations and consequences of managing PMSS without molecular confirmation or complete resection. A multidisciplinary approach with current diagnostic standards is essential in these high-risk pediatric tumors.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"2 3","pages":"163-166"},"PeriodicalIF":0.0,"publicationDate":"2025-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.70017","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145196797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pleural cavitations and pneumothorax following axitinib therapy in metastatic renal cell carcinoma: A case report","authors":"Feride Yılmaz,&nbsp;Serkan Yaşar,&nbsp;Figen Demirkazık,&nbsp;Zafer Arık,&nbsp;Mustafa Erman","doi":"10.1002/msp2.70014","DOIUrl":"https://doi.org/10.1002/msp2.70014","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Tumor cavitation and pneumothorax are uncommon yet serious complications of antiangiogenic therapies. These risks are particularly significant in patients with metastatic renal cell carcinoma (mRCC). Axitinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFRs), is generally used as a second-line treatment for mRCC. However, rare cases of lung metastases with cavitary lesions and pneumothorax have been reported after the use of axitinib. Therefore, we decided to report one of these rare cases.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case presentation</h3>\u0000 \u0000 <p>A 46-year-old male with mRCC developed pleural cavitations and secondary pneumothorax after starting axitinib therapy. Despite intensive management, his condition worsened with recurrent pneumothorax, ultimately leading to sepsis and multiorgan failure.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This case underscores the potential risks of tumor cavitation-induced pneumothorax in patients receiving axitinib. Close radiological monitoring and timely intervention are essential for reducing morbidity and mortality in such cases. Clinicians should remain vigilant for this rare but serious complication during axitinib therapy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"2 3","pages":"159-162"},"PeriodicalIF":0.0,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.70014","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145197015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A follow-up study of 25 patients with pancreatic cancer receiving gemcitabine and cisplatin and 21-h infusional 5-fluorouracil","authors":"Mozaffar Aznab,&nbsp;Arash Golpazir Sorkheh,&nbsp;Kiumars Eslsm Pia,&nbsp;Sayed Javad Hossini,&nbsp;Fatemeh Heydarpour","doi":"10.1002/msp2.70013","DOIUrl":"https://doi.org/10.1002/msp2.70013","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The purpose of this study was to assess clinical characteristics and survival of patients with advanced pancreatic cancer who were treated with gemcitabine, cisplatin, and 21-h infusional 5-fluorouracil (5-FU).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study was a prospective, observational study at a medical center in Western Iran. The clinical and survival data from 25 patients treated with gemcitabine, cisplatin, and 21-h infusional 5-FU at our center were prospectively assessed. Patients received chemotherapy consisting of cycles of continuous infusion of 5-FU (650 mg/m²) for 21 h on Days 1, 2, 3, and 4. Gemcitabine was administered at a dose of 1 g/m² on Days 1 and 8, and cisplatin was administered at a dose of 60 mg/m² on Day 1, with granulocyte colony-stimulating factor (G-CSF) support. Each cycle was repeated every 21 days for 5−6 cycles.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 25 patients with an age range of 39−73 years were studied. One out of the two patients with stage Ⅱ cancer survived for more than 43 months. Four out of the 14 patients with stage Ⅲ cancer survived for more than 15 months. Seventeen patients died, and eight subjects were alive at the end of the study. The mean and median of overall survival (OS) rates for the 25 patients were 20 and 12 months, respectively. The median progression-free survival (PFS) was 6 months.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>It seems that the triple therapy with gemcitabine, cisplatin, and infusional 5-FU afforded significant PFS and OS benefits in patients with advanced pancreatic cancer.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"2 3","pages":"140-144"},"PeriodicalIF":0.0,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.70013","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145196931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The result of maintenance therapy with rituximab in extra nodal lymphoma","authors":"Mozaffar Aznab,&nbsp;Fatemeh Heydarpur,&nbsp;Amirmasoud Rahimi,&nbsp;Sayed Javad Hossini,&nbsp;Kiumrs Eslampia","doi":"10.1002/msp2.70011","DOIUrl":"https://doi.org/10.1002/msp2.70011","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Maintenance treatment with rituximab has been used in some nodal lymphomas, such as follicular and diffuse large cell lymphoma. The aim of this study was to evaluate the survival of extra nodal lymphoma patients under maintenance treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and methods</h3>\u0000 \u0000 <p>From July 2008 to December 2017, after induction treatment in patients with extra nodal lymphoma, if the patients consented and the drug was available, they were treated with rituximab every 3 months for 2 years.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 112 patients with extra nodal lymphoma met the inclusion criteria. Among them, 89 patients had high-grade lymphomas and 23 patients were in the group of low-grade lymphomas. The group of patients with high-grade lymphoma who received the rituximab-containing regimen as a maintenance treatment had lower rates of recurrence and death compared to the group that received rituximab only in the induction phase. In patients with low-grade lymphoma, the recurrence rate and mortality were also lower in the group receiving maintenance treatment compared to other groups, but the difference was not statistically significant.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The use of rituximab in patients with extra nodal lymphoma as maintenance can increase the survival of the patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"2 2","pages":"95-102"},"PeriodicalIF":0.0,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.70011","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144519800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A gene panel to predict response to adjuvant chemotherapy and risk of recurrence in colorectal cancer","authors":"Steffie Urmila Avanthi,&nbsp;Ravikanth Vishnubhotla,&nbsp;Mitnala Sasikala,&nbsp;Guduru Venkat Rao,&nbsp;Rebala Pradeep,&nbsp;Sanjeev Marigowda Patil,&nbsp;Anuradha Sekaran,&nbsp;Jain Aviral,&nbsp;Sonali Mondkar,&nbsp;Nageshwar Reddy Duvvur","doi":"10.1002/msp2.70009","DOIUrl":"https://doi.org/10.1002/msp2.70009","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Chemotherapy is the mainstay to treat metastatic colorectal cancer (CRC). However, a sizeable proportion of patients do not respond to treatment, which leads to the recurrence of disease. This study was carried out to identify reliable gene expression-based marker(s) to predict the response to chemotherapy and the risk of recurrence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This prospective study involved the collection of tumor tissues (<i>n</i> = 100) and normal tissues (<i>n</i> = 10) from CRC patients who primarily underwent surgical treatment. Global gene expression profiles were generated on microarray (Affymetrix; <i>n</i> = 5) and the next-generation sequencing (NGS) (Illumina; <i>n</i> = 20) platforms. Patients were classified as responders (<i>n</i> = 13; complete response with no relapse) or non-responders (<i>n</i> = 12; recurrence of disease leading to death). Common dysregulated genes identified from both platforms were replicated in an independent set (<i>n</i> = 75; quantitative real-time polymerase chain reaction (qRT-PCR)). The area under the curve (AUC) was generated, and a combinatorial analysis was performed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 193 and 1351 genes were dysregulated in microarray and NGS datasets, respectively. Of the top common genes (<i>PTGIS</i>, <i>LYVE1</i>, <i>C3</i>, <i>C7</i>, <i>CXCL12</i>, <i>CEACAM6</i>, <i>MUC13</i>, and <i>ST14)</i> that were selected for replication, upregulation of five genes (<i>PTGIS</i>, <i>C3</i>, <i>C7</i>, <i>LYVE1</i>, and <i>CXCL12</i>) were associated with the non-responder group in validation set. Combinatorial analysis and comparison of AUC identified a significant increase (<i>p</i> = 0.03) in AUC by 15.2% (95% confidence interval (CI): 0.01−0.29) for two genes (<i>PTGIS</i> and <i>LYVE1</i>). Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were 88.9%, 100%, 100%, and 95.6%, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Assessing upregulation of the <i>PTGIS</i> and <i>LYVE1</i> genes enables identification of individuals who may not respond to adjuvant chemotherapy and the risk of recurrence. The addition of drugs targeting these genes may improve response and benefit the patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"2 2","pages":"84-94"},"PeriodicalIF":0.0,"publicationDate":"2025-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.70009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144520266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of miR-4284 in cancer progression and therapeutic response: Regulatory mechanisms and clinical implications","authors":"Chenhao Liang,&nbsp;Yaojie Feng,&nbsp;Yuhua Zhang,&nbsp;Zehua Wang,&nbsp;Xinming Su,&nbsp;Shiwei Duan","doi":"10.1002/msp2.70008","DOIUrl":"https://doi.org/10.1002/msp2.70008","url":null,"abstract":"<p>As a pivotal microRNA (miRNA), miR-4284 exhibits noteworthy aberrant expression levels across various cancers and diseases, exerting a crucial role in modulating cancer progression and prognosis. This article endeavors to comprehensively elucidate the regulatory mechanisms of miR-4284 in cancer, delving deeply into its impact on tumor cell proliferation, invasion, and metastasis by intervening in key signaling pathways such as p65, mitogen-activated protein kinase (MAPK), and transforming growth factor-β (TGF-β). Moreover, this article examines the potential associations of miR-4284 with diverse current therapeutic strategies, such as cancer prediction models, synergistic effects of chemotherapeutic agents, mechanisms of ultrasound-targeted microbubble destruction technology, and enhancement of radiotherapy. However, despite the significant strides made in miR-4284 research, certain limitations persist. Looking ahead, we anticipate that larger-scale and more in-depth studies will further unveil the functional mechanisms of miR-4284 and elucidate its role in therapeutic drug efficacy, thus furnishing robust theoretical underpinnings for the clinical application of miR-4284.</p>","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"2 2","pages":"59-73"},"PeriodicalIF":0.0,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.70008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144519833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heart failure during adjuvant therapy for breast cancer: A case report","authors":"Huan Zhang,&nbsp;Zhao Ma,&nbsp;Shuwen Yang,&nbsp;Linqi Liu,&nbsp;Shu Zhou,&nbsp;Lanxin Feng,&nbsp;Ran Ran,&nbsp;Wenyang Liu,&nbsp;Chenchen Tu,&nbsp;Xiantao Song,&nbsp;Hongjia Zhang","doi":"10.1002/msp2.70010","DOIUrl":"https://doi.org/10.1002/msp2.70010","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Breast cancer is one of the most common malignant tumors among women worldwide. Chemotherapeutic and targeted agents, as important adjuvant therapy for breast cancer, can also cause cardiotoxicity, leading to cardiac dysfunction. It is essential to recognize cardiotoxicity early, cease drug exposure when appropriate, and initiate heart failure therapy. Currently, echocardiography is routinely used to monitor cardiac function during treatment. However, normal left ventricular ejection fraction (LVEF) measured by echocardiography cannot exclude cardiotoxicity. Therefore, more sensitive cardiac monitoring tools are needed. Optical pumped magnetometer-magnetocardiography (OPM-MCG) has been proved to be a noninvasive and effective means to detect and monitor myocardial injury.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case description</h3>\u0000 \u0000 <p>In this case, we presented a patient diagnosed with early breast cancer with human epidermal growth factor receptor 2 (HER2) overexpression, following adjuvant therapy with paclitaxel liposomes, trastuzumab, and pertuzumab. Heart failure with reduced ejection fraction (HFrEF) occurred after five cycles of anti-HER2 therapy, which improved with chronic heart failure (CHF) treatment. The MCG scan of this patient was significantly abnormal when she developed symptomatic HFrEF, which improved gradually during CHF treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The patient's heart failure was most likely caused by HER2-targeted agents, which was reversible and could be improved with the administration of angiotensin receptor neprilysin inhibitor (ARNi) and sodium-glucose cotransporter-2 inhibitor (SGLT2i). In the future, OPM-MCG may act as a safe, accurate, and efficient evaluation tool for cardiotoxicity monitoring to detect early myocardial injury in cancer patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"2 2","pages":"110-115"},"PeriodicalIF":0.0,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.70010","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144520073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postoperative concurrent chemoradiotherapy utilizing intensity-modulated radiation therapy (IMRT) for a young adult male with primary tracheal carcinoma: A case report demonstrating 5-year long-term survival","authors":"Xueling Chen,&nbsp;Xuejian Ning,&nbsp;Tao Si","doi":"10.1002/msp2.70006","DOIUrl":"https://doi.org/10.1002/msp2.70006","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The incidence of primary tracheal neoplasm is extremely rare. Squamous cell carcinoma (SCC) is the most prevalent histological type of tracheal malignancy. Postoperative adjuvant radiotherapy can be considered as a curative management option. However, there are limited data available on the use of radiotherapy or concurrent chemoradiotherapy for tracheal cancer, particularly intensity-modulated radiotherapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Patient and methods</h3>\u0000 \u0000 <p>Herein, we present a case report of a young adult male diagnosed with primary SCC of the trachea who underwent postoperative concurrent chemoradiotherapy utilizing intensity-modulated radiation therapy (IMRT). The treatment included 50.4 Gy radiation in 28 fractions and two cycles of chemotherapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The patient experienced grade Ⅰ dermatitis and grade Ⅱ granulocytosis. Follow-up showed no evidence of recurrence or significant adverse effects. The patient achieved 5-year long-term survival with good quality of life.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Postoperative concurrent chemoradiotherapy using IMRT is effective for primary tracheal carcinoma, offering long-term survival and quality of life benefits.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"2 2","pages":"103-109"},"PeriodicalIF":0.0,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.70006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144520069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}